Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed · Phase 3 · Has a placebo group

Conditions studied: Infections, Meningococcal

In brief

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).

Key facts

Study ID

NCT03621670

Run by

GlaxoSmithKline

People needed

1196

Starts

2018-07-27

Expected to finish

2024-12-27

Last updated by the study team

2026-02-10

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All subjects must satisfy all the following criteria at study entry:
• Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits).
• Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
• A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination.
• Healthy subjects as established by medical history and clinical examination before entering into the study.
• Born full-term (i.e. after a gestation period of ≥ 38 weeks).

You may not qualify if…

• If any exclusion criterion applies, the subject must not be included in the study:
• Child in care
• Each subject must not have:
• Progressive, unstable or uncontrolled clinical conditions.
• Hypersensitivity, including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study.
• Hypersensitivity to latex.
• Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
• Abnormal function of the immune system resulting from:
• Clinical conditions.
• Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth.
• Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth.
• Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
• Received immunoglobulins or any blood products from birth.
• Received an investigational or non-registered medicinal product from birth.
• Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
• Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions).
• Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders).
• Study personnel as an immediate family or household member.
• Current or previous, confirmed or suspected disease caused by N. meningitidis
• Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization.
• Previous administration of meningococcal B or pneumococcal vaccine at any time prior to informed consent.
• Received a dose of DTPa-HBV-IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed.
• Serious chronic illness.
• Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS).

Where it is running

• GSK Investigational Site — Fayetteville, Arkansas, United States
• GSK Investigational Site — Jonesboro, Arkansas, United States
• GSK Investigational Site — Anaheim, California, United States
• GSK Investigational Site — Oakland, California, United States
• GSK Investigational Site — Roseville, California, United States
• GSK Investigational Site — Walnut Creek, California, United States
• GSK Investigational Site — West Covina, California, United States
• GSK Investigational Site — Lake Mary, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Nampa, Idaho, United States
• GSK Investigational Site — Nampa, Idaho, United States
• GSK Investigational Site — Newton, Kansas, United States
• GSK Investigational Site — Topeka, Kansas, United States
• GSK Investigational Site — Bardstown, Kentucky, United States
• GSK Investigational Site — Louisville, Kentucky, United States
• GSK Investigational Site — Louisville, Kentucky, United States
• GSK Investigational Site — Louisville, Kentucky, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Fall River, Massachusetts, United States
• GSK Investigational Site — Bingham Farms, Michigan, United States
• GSK Investigational Site — Kansas City, Missouri, United States
• GSK Investigational Site — Lincoln, Nebraska, United States
• GSK Investigational Site — Omaha, Nebraska, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.